Therapeutic

Dual-action vaccine turns cancer on itself

Dual-action vaccine turns cancer on itself

In findings from Brigham and Women’s Hospital published in Science Translational Medicine in January 2023, researchers reveal newly discovered potential to exploit cancer cells in the fight against cancer. Using a “dual-action, cancer-killing vaccine” in an advanced...

Cancer vaccine potential in 2023: mRNA moves forward

Cancer vaccine potential in 2023: mRNA moves forward

Towards the end of 2022 we noted the positive results of a Moderna/Merck trial for a personalised cancer vaccine in combination with KEYTRUDA therapy. After the mRNA momentum of the pandemic, there appears to be a sense of optimism in the therapeutic community for the...

Moderna and Merck meet mRNA melanoma efficacy endpoints

Moderna and Merck meet mRNA melanoma efficacy endpoints

In December 2022 Moderna and Merck announced positive results from a Phase IIb trial of mRNA-4157/v940, an investigational personalised cancer vaccine, in combination with Merck’s anti-PD-1 therapy KEYTRUDA. In this trial, the combination approach demonstrated a...

Exclusive interview with Dr Stephen Johnston

Exclusive interview with Dr Stephen Johnston

As we gear up towards the World Vaccine and Immunotherapy Congress in San Diego later this month we have been meeting a few of our speakers to get some exclusive insights before their sessions. Dr Stephen Johnston will be representing Calviri Inc. as founding CEO....

AELIX Therapeutics study in Nature meets endpoints

AELIX Therapeutics study in Nature meets endpoints

In November 2022 the results of the AELIX-002 trial were published in Nature by collaborators from Aelix Therapeutics and Gilead Sciences. This is the trial that Dr Christian Brander, Co-founder and Chief Scientific Officer at Aelix Therapeutics, hinted at in our...

Exclusive interview with Dr Andrew Vaillant

Exclusive interview with Dr Andrew Vaillant

As we look back on the Congress in Europe and forward to future events, a conversation with Dr Andrew Vaillant of Replicor links our event in Barcelona to the World Vaccine and Immunotherapy Congress in San Diego. As Chief Scientific Officer with 20 years’ experience,...

Glioblastoma vaccine offers longer life to patients

Glioblastoma vaccine offers longer life to patients

In a study published in JAMA Oncology in November 2022, researchers from America and Europe collaborated to demonstrate “clinically meaningful and statistically significant extension of survival” for patients with glioblastoma. The results are described as...